In a report published Wednesday, Jefferies analyst Eun K. Yang reiterated a Buy rating on Opko Health OPK, and slightly raised the price target from $8.00 to $9.00.
In the report, Yang noted, “Estimated current cash of ~$187M including converts net proceeds in 01/13 should be sufficient thru 2016. Upcoming Ph3 data include partner Tesaro's (TSRO, $23.97, NC) rolapitant in 2H13 and OPK's CTAP101 in 1H14. Recent nephrologists discussions indicate a high bar for new SHPT drugs; our estimated ~$350M in potential CTAP101 sales in predialysis could be aggressive (70% probability assumed in valuation).”
Opko Health closed on Tuesday at $7.52.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in